Endothelial, platelet, and macrophage microparticle levels do not change acutely following transcatheter aortic valve replacement

Autor(es)

Marchini, Julio F. ^{[1, 2]} ; Miyakawa, Ayumi Aurea ^[1] ; Tarasoutchi, Flavio ^[3] ; Krieger, Jose Eduardo ^[1] ; Lemos, Pedro ^[2] ; Croce, Kevin ^[4]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Med, Inst Heart, Lab Genet & Mol Cardiol, Sao Paulo, SP - Brazil

^[2] Univ Sao Paulo, Sch Med, Inst Heart, Hemodynam & Intervent Cardiol Serv, Sao Paulo, SP - Brazil

^[3] Univ Sao Paulo, Sch Med, Valvular Heart Dis Unit, Sao Paulo - Brazil

^[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA - USA

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF NEGATIVE RESULTS IN BIOMEDICINE; v. 15, APR 11 2016.
• Citações Web of Science: 0

Resumo

Background: Patients with severe aortic stenosis have increased levels of prothrombotic and proinflammatory microparticles (MP), and MPs actively regulate pathological processes that lead to atherothrombotic cardiovascular events. Shear stress is a validated stimulus of MP production, and abnormal shear stress in aortic stenosis increases MP release in ex-vivo studies. We hypothesized that in patients with severe aortic stenosis, percutaneous replacement of the aortic valve (TAVR) would reduce abnormal shear stress and would decrease levels of circulating MPs. Findings: The experimental protocol utilized flow cytometry (FC) and nanoparticle tracking analysis (NTA) to quantify circulating plasma MP levels in aortic stenosis patients at baseline and 5 days after TAVR. The baseline and 5 day MP counts measured by FC were 6.10.10(5) +/- 1.21.10(5) MP/mu L and 5.74.10(5) +/- 9.54.10(4) MP/mu L, respectively (p = 0.91). The baseline and 5 day MP counts measured by NTA were 9.29.10(13) +/- 1.66.10(13) MP/mu L and 3.95.10(14) +/- 3.11.10(14) MP/mu L, respectively (p = 0.91). When MPs were stratified by cell source, there was no difference in pre/post TAVR endothelial, platelet, or leukocyte MP levels. Conclusion: Levels of circulating MPs do not change acutely following TAVR therapy for aortic stenosis. Trial registered at clinicaltrials. gov NCT02193035 on July 11, 2014. (AU)

• Processo FAPESP: 13/17368-0 - Genômica cardiovascular: mechanismos & novas terapias - CVGen mech2ther
• Beneficiário: José Eduardo Krieger
• Modalidade de apoio: Auxílio à Pesquisa - Temático